Dose, Effects and Characteristics of Pilocarpine
1 other identifier
interventional
37
1 country
1
Brief Summary
The purpose of this investigation, in which pilocarpine was given in repeated doses, was to evaluate: Part I - the effects of different concentrations of pilocarpine hydrochloride on intraocular pressure. Part II -the effects on intraocular pressure of glaucomatous patients to pilocarpine 2% when given once, twice and four daily. In addition, we studied various attributes of the eye which may serve as indicators of responsiveness of individual patients to pilocarpine.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Aug 1978
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 1978
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 1979
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 1979
CompletedFirst Submitted
Initial submission to the registry
December 5, 2008
CompletedFirst Posted
Study publicly available on registry
December 8, 2008
CompletedNovember 22, 2016
November 1, 2016
1 year
December 5, 2008
November 20, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Intraocular Pressure
25 days
Study Arms (2)
Pilocarpine Concentration
EXPERIMENTALVarying concentration 0.5 to 8% - 22 patients were examined regarding: visual acuity, iris color, pupil size, chamber angle, C/D ratio, visual field (VF), coefficient of aqueous outflow and Goldmann tonometry. After a one month washout period, pilocarpine was used 4 times daily, in concentrations from 0.5 to 8%. The amount of IOP change was compared with various clinical findings
Pilocarpine Frequency
EXPERIMENTALVarying frequency, once to four times daily - 15 patients were included in a crossover study: IOP was checked daily for 3 days and for 9 hours on fourth day. Pilocarpine was started on day 5 once daily OD and BID OS; on day 9 once daily OD and QID OS; on day 12 QID OD and once daily OS; on day 16 once daily OD and QID OS; and on day 19 QID OD and once daily OS. No medications were used on days 23-25. IOP was measured on days 4, 8, 11, 15, 18, 22 and 25.
Interventions
Eligibility Criteria
You may qualify if:
- Primary open-angle glaucoma
- Primary open-angle glaucoma suspect
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Wills Eyelead
Study Sites (1)
Wills Eye Glaucoma Service
Philadelphia, Pennsylvania, 19107, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
George L Spaeth, MD
Wills Eye Glaucoma Service
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Attending Surgeon
Study Record Dates
First Submitted
December 5, 2008
First Posted
December 8, 2008
Study Start
August 1, 1978
Primary Completion
August 1, 1979
Study Completion
December 1, 1979
Last Updated
November 22, 2016
Record last verified: 2016-11
Data Sharing
- IPD Sharing
- Will not share